Market Highlights
The Hyperhidrosis Treatment Market Size is anticipated to reach
USD 1.50 Billion by 2032 at 5.90% CAGR during the forecast period 2023-2032.
The growth of the global Hyperhidrosis Treatment Market is driven
by various factors such as rising research and development activities for
developing novel approaches for hyperhidrosis treatment, increasing awareness
activities and campaigning about hyperhidrosis, upsurge in the usage of
botulinum toxin injections, advancement in the therapeutic approaches such as
laser and electronic therapy, increasing support by public and private
companies. On the other hand, unavailability of the permanent clonidine for
hyperhidrosis, and expensive treatment options are some factors that may
hinder the growth of the hyperhidrosis market to an extent.
Hyperhidrosis is a condition in which the affected person
experiences excessive sweating. Hyperhidrosis can be divided into two
types—primary hyperhidrosis and secondary general hyperhidrosis. Primary
hyperhidrosis is the most common type, with 80% of people are affected by it.
Key Players
The global hyperhidrosis
treatment market players are
Allergan PLC (Ireland),
Brickell Biotech Inc. (US),
Cynosure (US),
Dermadry Laboratories inc. (Canada),
Dermira Inc. (US),
GlaxoSmithKline PLC (UK),
Miramar Labs, Inc. (US),
Sesderma (Spain), and
Ulthera Inc. (US).
The global hyperhidrosis treatment market is currently scattered,
and no particular player is dominating the market. This is mainly due to the
different types of therapeutic approaches being used to treat the disorder.
However, few key players are involved in the new product launches and other
developments to strengthen their market positions. For instance, in June 2018,
Dermira received the Food and Drug Administration (FDA) approval for Qbrexza
(glycopyrronium), a topical treatment for primary axillary hyperhidrosis
(excessive underarm sweating).
Segmentation
The global hyperhidrosis
treatment market insights has been segmented based on type, treatment,
and end-user.
·
The market, based on type, has been
divided into primary hyperhidrosis and secondary generalized hyperhidrosis. The
primary hyperhidrosis segment is likely to hold the largest during the review
period due to the large population being affected by the primary hyperhidrosis.
Besides being largest, it is also predicted to be the fastest-growing segment
due to the increasing awareness about the condition and increasing patient
population opting for the aesthetic procedures in order to manage the medical
condition.
·
on the basis of treatment, into
botulinum toxin injections, topical treatment, surgical treatment, oral
medication, microwave therapy, and others. The topical treatment segment is
expected to hold the maximum share of the market owing to the wide acceptance
of the topical products, convenience of use, and fewer risks compared to other
therapies. The botulinum toxin injections segment is expected to be the
fastest-growing due to the rising awareness about the treatment and high per
capita disposable incomes in developed countries.
·
The end-users of the market are
dermatology clinics, ambulatory surgery centers, payers/patients, and others.
The payers/patients segment is expected to hold the largest share of the
market. This is attributed to factors such as patient’s easy access to the
topical treatments, high commercial availability, and convenience in use as
compared to other treatment options. The dermatology clinics segment is
expected to be the fastest growing owing to the increasing adoption of
aesthetic procedures for the management of hyperhidrosis.
Regional Analysis
The market has been divided, by region, into the Americas, Europe,
Asia-Pacific, and the Middle East & Africa. The Americas is expected to be
the largest market owing to the increased awareness about hyperhidrosis
treatment and high per capita disposable incomes. The hyperhidrosis treatment
market in the Americas has further been branched into North America and Latin
America, with the North American market divided into the US and Canada. The
European hyperhidrosis treatment market has been categorized as Western Europe
and Eastern Europe. The Western European market has further been divided as
Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The
hyperhidrosis treatment market in Asia-Pacific has been segmented into Japan,
China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the
rising per capita healthcare expenditure and growing awareness towards the
management of hyperhidrosis, the market in Asia-Pacific is expected to be the
fastest-growing. The hyperhidrosis treatment market in the Middle East &
Africa has been divided into the Middle East and Africa.
About US:
Market Research Future (MRFR) enable customers to unravel the
complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
